🇺🇸

US SEC Filing Intelligence

· daily

Nasdaq 100 Stocks SEC Filings — October 28, 2026

Across the 12 filings, the NASDAQ-100 mega-cap cohort shows strong top-line momentum led by cloud and AI infrastructure: Alphabet reported revenue up 25% YoY with Google Cloud up 103%, Microsoft grew revenue 18.8% with Microsoft Cloud up 30%, and T-Mobile's Q3 revenue rose 7.4% with net income up 27.3%. Earnings quality is the common weak point: GAAP results at Microsoft and Alphabet were inflated or distorted by investment mark-to-market swings (Microsoft's other income swung from a $3,660M expense to $38M gain, and the OpenAI gain of $207M versus a $3.1B prior-year loss flatters the 32% GAAP EPS growth versus 18% non-GAAP; Alphabet's net income fell 25% as other expense of $8,221M replaced a $12,759M gain). Capital intensity is rising sharply: Microsoft's property and equipment capex more than doubled to $39,367M, while Alphabet's long-term debt jumped to $125,102M from $46,547M at year-end 2025 with $28.7B of senior notes and $12.4B of ATM equity issuance. Capital returns remain robust, with T-Mobile repurchasing $9,564M over nine months (up 27.1%) and ADP lifting treasury stock via $758.8M of buybacks. Insider selling at Meta and Intuitive Surgical was uniformly under Rule 10b5-1 plans and is best read as routine diversification rather than a conviction signal. Market implication: the market is rewarding revenue acceleration in AI and cloud but will increasingly scrutinize GAAP quality, financing needs, and free cash flow conversion.

9 high priority 3 medium 12 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — October 28, 2026

This digest covers 50 SEC filings dated October 28, 2026 that fall within the Activist & Institutional Activity stream, focused on Major Shareholder events. The dominant pattern is passive institutional disclosure: roughly 35 of the 50 filings are Schedule 13G or 13G/A ownership reports under Rules 13d-1(b), (c) or (d), many from Bank of America subsidiaries reporting small stakes (typically 0.0% to 7% of class) with sole or shared power and no control intent. The most material developments are the activist and control-oriented filings: Trian Partners' Amendment No. 65 on The Wendy's Company describing a proposed take-private-style transaction with no financing condition, People Incorporated's voting agreement capping MGM Resorts ownership at 29.9% and voting at 25.73%, SunHydrogen's 42.7% strategic stake in NewHydrogen with board representation intent, Saba Capital's net-selling position in Adams Natural Resources Fund near NAV-discount prices, and HoldCo Opportunities' 5.0% stake in BankUnited with stated engagement with management. Several filings signal full exits or cessations of 5%+ status (Nathan's Famous after the Smithfield acquisition, Weave Communications after the Francisco Partners take-private, Cardinal Infrastructure, Hennessy Capital VII, Visium Technologies' former CEO), and the period-over-period data in the filings is largely limited because most 13G filings do not report prior-period comparisons, so trend analysis rests mainly on event dates, cap-table denominators and the explicit disclosures of sales, transfers and exits.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — October 28, 2026

Across the 13 filings, the dominant theme is a split between strong top-line growth and weaker bottom-line quality among large financials. Robinhood posted record Q3 revenue of $1.42B (+12% YoY) and 5.2M Gold subscribers, yet net income fell 14% YoY and operating expenses rose 16%, with crypto revenues down 55%. Wells Fargo showed revenue of $21.87B (+2% YoY, -3% QoQ) and net income of $5.95B (+6% YoY), but its efficiency ratio deteriorated to 63% from 60% and NIM compressed to 2.43% from 2.61%. Truist's Q3 net income fell 45% YoY to $799M on a $1.45B securities loss, though its nine-month investment banking and trading income rose 30.8%. Chubb grew nine-month net income 12.9%, but a $(4.8)B unrealized fixed-maturity depreciation pushed Q3 comprehensive income to a loss and cut equity to $78.5B from $79.8B. S&P Global's Q3 revenue rose 6.8% YoY, yet net income attributable grew only 5.4% after a discontinued-operations swing and the Mobility Global separation, with short-term debt rising to $2.45B from $0.72B. Insider activity skewed to sales at Travelers (EVP sold 11,000 shares, ~$4.33M) and Chubb (EVP sold ~$4.6M), while Price T. Rowe and BlackRock activity was small. Capital return remained a consistent support: Wells Fargo dividends rose 11% YoY to $0.50, Truist repurchased $3.57B year-to-date, and S&P Global bought back $4.1B in treasury shares over nine months.

10 high priority 3 medium 13 total filings
· daily

S&P 500 Energy Sector SEC Filings — October 28, 2026

Across the eight S&P 500 Energy filings dated 2026-10-28, the dominant theme is a sharp refining and margin-driven earnings rebound alongside aggressive capital returns and large balance-sheet transactions. Valero reported Q3 revenue up 43.3% YoY to $46,098M with net income of $6,828M versus $1,095M, while Phillips 66 posted adjusted earnings of $5.6B ($14.08/share) driven by refining realized margins rising to $24.08/BBL from $13.92/BBL. Both companies continued heavy buybacks ($3,396M at Valero; $2,921M year-to-date at Phillips 66), signaling confidence in cash generation. Oilfield services presented a more mixed picture: SLB grew total revenue 5.8% YoY to $9,449M, but cost of sales rose 14.7% and net income was roughly flat, and Baker Hughes' revenue rose 14.5% while net income fell 32.5% as interest expense and acquired-intangible amortization surged following the Chart Industries acquisition. Balance-sheet leverage is a clear watch point: Baker Hughes' long-term debt rose to $17,476M from $5,398M, while ONEOK is deleveraging ($30,755M to $26,935M) using Apollo's $9,000M Class B contribution and a pending $1,200M Brazos Midland acquisition. The earnings quality of several headline gains is questionable, since Baker Hughes' nine-month profit was lifted by a $697M disposition gain and Valero's Q3 is heavily margin-driven and volatile. Insider activity was light and largely routine (SLB CEO 10b5-1 sale; Expand Energy CEO equity awards), providing little signal on management conviction.

7 high priority 1 medium 8 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — October 28, 2026

Three SEC filings dated 2026-10-28 were reviewed for the USA S&P 500 Consumer Staples stream. Coca-Cola's 10-Q shows the strongest fundamentals: Q3 net operating revenues rose 7.4% YoY to $13,380 Million and diluted EPS grew 8.1% to $0.93, with nine-month net income up 14.1%, though SG&A growth of roughly 9.9% outpaced revenue and a $(668) Million FX translation hit compressed Q3 comprehensive income 17.4%. Year-to-date dividends paid nearly doubled to $6,842 Million from $4,391 Million, a notable shift in capital allocation. Hershey's Form 4 reflects a 10% owner trust selling 7,547 shares at about $163.61 (~$1.23M) and 11 transactions in total under a Rule 10b5-1 plan, leaving 486,119 shares held, which is a routine diversification pattern rather than a fundamental signal. Kimberly-Clark's 8-K extends the Kenvue exchange offer expiration to November 2, 2026 for up to $7.0 billion of notes, with consents already received, signalling the Kenvue acquisition is progressing toward settlement. The filings contain no guidance changes, so the near-term catalyst path is the Kenvue closing and Coca-Cola's margin trajectory.

2 high priority 1 medium 3 total filings
· daily

S&P 500 Industrials Sector SEC Filings — October 28, 2026

Across the 12 filings, the dominant theme is strong top-line and guidance momentum paired with uneven segment quality and heavy balance-sheet activity. GE Vernova stands out with Q3 revenue up 26.8% YoY to $12,642M, orders of $29.3B (+96% organically), backlog of $197B, a raised 2026 outlook and a $9.0B Trench Group acquisition, though its nine-month net income of $6,704M is inflated by a $4,947M non-recurring other-income gain. FedEx shows the sharpest divergence: Q2 revenue rose 11.9% YoY to $22,855M and adjusted EPS guidance was raised to $18.00-$18.60, yet GAAP net income fell roughly 55% in the quarter on a $1,238M investment loss and fuel expense jumped 63.9%. Honeywell Aerospace (HONA) combines a reported 2.4% sales gain with 29.1% lower nine-month net income and a swing to $(2,489)M total equity after its spin-off, funded by $15,853M of new long-term debt. Otis and ITW show the flip side of the cycle: Otis China New Equipment sales fell over 20% and New Equipment margin contracted 150 bps to 3.2%, while ITW's Automotive OEM and Construction Products segments declined or stayed flat. Capital returns remain robust (GE Vernova's $20B buyback authorization, FedEx's $2.0B of repurchases, ADP's $758.8M quarterly buyback), but cash conversion is weakening at Otis, where adjusted free cash flow fell 19.3%.

6 high priority 6 medium 12 total filings
· daily

US Material Events SEC 8-K Filings — October 28, 2026

Across the 50 filings for the Material Events Monitor (28 Oct 2026), the dominant theme is leadership transition and governance churn: at least 12 filings involve CEO, CFO, COO, CAO or director changes (Enanta, Align, Q2 Holdings, Parsons, Radian, Compass Minerals, ABM, Monroe Federal, LENZ, Garrett Motion, Bausch & Lomb, Red Robin). Corporate-control and M&A activity is heavy, led by EnerSys/Ultralife (~$320M all-cash, 166% premium), Enerpac/SFE Group (~$472M, 10.6x trailing EBITDA), B. Riley's short-form merger, and GE HealthCare's $945M SOFIE acquisition. Earnings-driven signals are split: HF Sinclair (net income $2,015M vs $403M, refining margin $54.22/bbl) and GE HealthCare (Adj. EBIT margin +180 bps, guidance raised) show strong momentum, while Nextpower (GAAP gross margin 31.1% vs 35.9% QoQ), LENZ (net loss $31.0M vs $16.7M) and Regional Management (credit loss rate +70 bps to 10.9%) show deteriorating quality beneath headline growth. Capital-raising and financing activity is prominent (AXT's RMB 1.9–3.7B Tongmei raise, Actuate's $11.0M offering, GCI Liberty's $270M term loan, SPACCircle's $100M IPO), and auditor changes at two SPACs/small caps (Ocean Power, AlphaTime) carry going-concern and material-weakness flags. Several filings were administrative or off-theme and were excluded from the digest.

50 high priority 50 total filings
· daily

Insider Trading Pulse — October 28, 2026

The Insider Trading Pulse for 2026-10-28 covers 50 SEC Form 4 filings, and the dominant story is heavy insider selling concentrated in DRDGOLD LTD, where eight officers exercised conditional share awards and sold shares at a uniform $2.44, a pattern that suggests a coordinated liquidity event rather than discretionary timing. Counterbalancing this, several accumulation signals emerged: Accenture's Chair and CEO bought roughly $2.49M of stock at $246.17, XBiotech's director bought about $711K, and Huntington Bancshares directors bought preferred shares alongside a cluster of routine director equity awards. Bank and financial names show mixed activity, with Fifth Third's CIO and State Street's Chief Risk Officer selling under 10b5-1 plans, while Huntington insiders were largely recipients of awards rather than sellers. Large-value sales in the scope included Travelers' EVP selling about $4.33M after an option exercise and Roper's CLO selling about $1.57M, both material to materiality scoring. Several filings carry no enriched period-over-period, guidance, or capital allocation data, so the digest cannot assess quantitative trend shifts and relies on transaction-level signals. Overall the day skews toward insider distribution in value terms, but the Accenture and XBiotech purchases are the clearest conviction signals.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — October 28, 2026

Across the eight Dow Jones 30 filings dated October 28, 2026, the dominant theme is strong top-line growth undercut by non-operating noise and heavy capital deployment. Alphabet (revenue +25% YoY to $127.6B, Cloud +103%) and Microsoft (revenue +18.8%, Microsoft Cloud +30%) both posted robust operating growth, but GAAP net income in both cases was distorted by swings in other income: Alphabet's net income fell 25% as an $8.2B other expense replaced a $12.8B gain, while Microsoft's 32% net income growth was flattered by a swing from a $3.7B expense to a $38M gain tied largely to OpenAI investment marks. Coca-Cola grew revenue 7.4% and nine-month net income 14.1%, but Q3 comprehensive income fell 17.4% on a $(668)M FX translation hit and year-to-date dividends nearly doubled to $6.8B. Honeywell's aerospace spin-off dominates its filings, with equity swinging to a $(2.5)B deficit, $15.9B of new long-term debt, and an inaugural $0.40 quarterly dividend alongside raised second-half free cash flow guidance. Capital intensity is a portfolio-level pattern: Microsoft capex more than doubled to $39.4B and Alphabet's long-term debt rose to $125.1B from $46.5B, with both leaning on external financing. Insider activity was limited to a Travelers filing outside this stream's scope in practice, so management-conviction signals are thin this cycle, and the net takeaway is that headline growth is intact but earnings quality and balance-sheet leverage warrant closer scrutiny than reported EPS suggests.

7 high priority 1 medium 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 28, 2026

Both filings in this window are Nasdaq listing-compliance events rather than bankruptcy or going-concern filings, which places them squarely within the stream's Delisting scope. Milestone Pharmaceuticals received a deficiency notice after 30 consecutive business days below $1.00, with a 180-day cure window to April 21, 2027, so the immediate listing impact is nil but the path to a reverse split or Capital Market transfer is open. OSR Health is further along the distress curve: Nasdaq's Hearings Panel denied continued listing on October 23, 2026, after a trading suspension already in place since August 26, 2026, and the stock now trades OTC while the company remains SEC-reporting. The enriched data for these filings does not include period-over-period financial comparisons, forward guidance, insider transactions, or capital allocation changes, so the analysis rests on the filing narratives and deal terms rather than quantified trend data. The common thread is sub-$1 equity pricing forcing exchange-level remediation, and OSR's $15M VXM01 put settlement via convertible notes at $2.00 to $5.00 per share signals dilution-driven funding under stress. The dated catalysts are OSR's promised update by November 6, 2026 and Milestone's April 21, 2027 cure deadline.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — October 28, 2026

This digest covers a stream focused on critical market events (bankruptcy, insolvency, M&A, delisting, tender/open offers, governance and enforcement actions) across the 50 pre-analyzed US SEC and Indian exchange filings dated 2026-10-28. The dominant theme is restructuring and control-change activity: several Indian insolvency and capital-reduction situations (Ashapura Intimates, Talwalkars Better Value Fitness, Gujarat Toolroom, BIL Vyapar) involve near-total cancellation of promoter or public holdings and dilutive preferential issues. A second cluster is US SPAC and M&A activity, including the EnerSys/Ultralife two-step tender at $16.00 per share and the Enerpac acquisition of SFE Group (~$472M, 10.6x trailing adjusted EBITDA, pro forma leverage ~2.3x). Period-over-period data is sparse in this batch, but where present it is mixed: Moschip reported a consolidated quarterly total income decline of 19% YoY with a widening net loss, Hexaware and Meesho disclosed subsidiary-level capital infusions without reported results, and EIML/EWAL carve-outs at Emkay show the wealth business at ~6.1% of consolidated income. Insider and sponsor-related activity is notable in several SPACs (JAB consulting fees, Wintergreen extension notes) and the Halfcourt S-4. Overall, the batch signals heightened governance and capital-structure event risk in micro/small-cap Indian issuers and SPAC shells, alongside a few large, well-documented cash acquisitions.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — October 28, 2026

Across 50 SEC filings dated October 28, 2026, the dominant theme is a sharp divergence between AI/data-center and industrial-electrification beneficiaries and consumer, legacy-pharma, and cross-border-financing names. Vertiv (+61% YoY net sales, guidance raised $650M), SK hynix (Q3 revenue up 327.9% YoY, Won 100 trillion FY26 shareholder-return target) and Generac (C&I +28% on data-center demand) show the strongest period-over-period momentum, while Vans (-9.8% YoY), Biogen's core MS franchise (-13% YoY), Otis New Equipment China (sales down over 20%) and Braskem's distressed extrajudicial reorganization illustrate the weakness. Capital returns are accelerating among winners, with SK hynix, TTM Technologies and SiteOne expanding buyback capacity, while leverage is rising at others (SiteOne net debt +24% YoY, Del Monte long-term debt $482.5M vs $173.0M at year-end 2025, Biogen net debt approx. $6.4B). Corporate-control activity is elevated, with LCI Industries facing a competing Monomoy proposal alongside its Patrick merger, Kimberly-Clark extending Kenvue exchange offers, and Ares Capital agreeing to buy MidCap Financial for roughly $2.5B. Most of the 50 filings are administrative 6-K or 13F disclosures with no quantified content, so signal density is concentrated in roughly 20 filings with substantive numbers.

5 high priority 45 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 28, 2026

Across the 12 newly filed Consumer Discretionary documents for 2026-10-28, the dominant theme is strong top-line growth paired with margin pressure. Carvana (revenue +42% YoY to $8.04B, retail units +39%) and eBay (GMV +15%, revenue +14%) are growing fast, yet both show compression in unit economics or operating margins, with Carvana's Total GPU down $365 and eBay's non-GAAP operating margin down 70 bps to 26.3%. Ford shows a mixed picture: revenue fell 2% and wholesale units fell 9%, but the low end of adjusted EBIT guidance was raised to $10.5B-$11B and Ford Credit EBT rose 27%. MGM Resorts is the most event-heavy name, with a Q3 attributable net loss of $17M (vs $285M), Las Vegas Strip EBITDAR down 12%, and a governance reset after People Inc.'s withdrawn acquisition proposal and an amended Voting Agreement capping ownership at 29.9%. Chipotle grew revenue 9.6% but saw operating margin fall to 13.7% from 15.9% on labor and G&A pressure. O'Reilly was the clear outlier on the positive side, with record revenue of $5.12B, comparable sales +7.2%, and a raised full-year outlook, though part of its EPS gain came from a one-time $39M tariff refund. Several names (Carvana's shift to GAAP-based targets and dropping outlooks, eBay's wide GAAP/non-GAAP gap, MGM's ownership and voting constraints) raise disclosure and visibility questions for investors. Ford's and Las Vegas Sands' debt and capital actions are the other notable developments.

5 high priority 7 medium 12 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 28, 2026

Four filings were provided for the S&P 500 Healthcare stream, of which three are in scope: two Biogen filings (8-K and 10-Q for Q3 2026) and one Boston Scientific 8-K, plus a Intuitive Surgical Form 4. Biogen posted total revenue of $2.804B (up ~11% YoY) with Growth Portfolio revenue up 49% YoY on the Apellis acquisition, but GAAP EPS swung to $(0.14) from $3.17 and Non-GAAP EPS fell 46% to $2.62, driven by $284M of acquired IPR&D and a net debt load of ~$6.4B that pushed other expense to $137M. Core MS franchise revenue fell 13% YoY and VUMERITY dropped 11%, while Biogen nudged its FY2026 Non-GAAP EPS guidance floor up to $12.20. Boston Scientific grew net sales 1.5% YoY with a mixed mix (Neuromodulation +13.0%, Urology -3.1%, U.S. +0.5%), GAAP EPS fell ~22%, and Q4 2026 guidance points to a 1.0–3.0% sales decline, a sharp deceleration despite raised full-year reported growth guidance of ~4.25%. Intuitive Surgical's disclosed insider activity is small (routine 10b5-1 sales) and carries little signal. The dominant theme is acquisition-driven top-line growth coming at the cost of earnings quality and balance-sheet leverage, with mature franchises under pressure.

2 high priority 2 medium 4 total filings
· daily

US Earnings Financial Results SEC Filings — October 28, 2026

Across 50 SEC financial filings for the period, earnings momentum is broadly positive on the top line but uneven beneath it: most in-scope companies posted revenue growth, yet many saw margin pressure from SG&A and G&A outpacing sales, rising interest expense, and working-capital build (inventories and receivables). Headline net income is frequently distorted by non-recurring items such as discontinued operations swings, disposition or remeasurement gains (Fortive, ONEOK, Baker Hughes, GE Vernova, Phillips 66, Tyler Technologies), and tax-rate shifts (TTM Technologies, Benchmark), so reported earnings growth overstates core performance in several names. Balance-sheet leverage rose materially at acquisition-heavy companies (Baker Hughes with long-term debt up to $17.5B from $5.4B, Biogen on Apellis, Cadence with $2.1B of cash paid for business combinations, Parsons, GE HealthCare), while capital returns remained aggressive (Masco's $852M buybacks pushed equity negative, Phillips 66 $2.9B repurchases, Valero $3.4B in the quarter, Coca-Cola dividends nearly doubling year-to-date). Weakest fundamentals sit with micro-cap and distressed names (Vanguard Green, MGP Ingredients' $180.8M impairment, Seacor Marine, Amarin), while energy and materials cyclicals (Valero, Phillips 66, ONEOK) show outsized profit swings tied to margin environments. Investors should differentiate between operating trend and one-time items when sizing positions in this cohort.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 28, 2026

This digest covers 11 DEF 14A and DEFM14A filings in the Executive Compensation Insights stream, all dated around October 28, 2026. The filings are overwhelmingly procedural: most contain no quantified financial results, so period-over-period comparisons (YoY/QoQ) are unavailable for nearly every company, and the enriched data is largely limited to governance, voting mechanics, and meeting logistics. The most material development is Distribution Solutions Group's going-private merger led by CEO J. Bryan King, which carries a 9/10 materiality score, a December 31, 2026 outside date, a dual-majority disinterested-stockholder vote requirement, and roughly $189 million in recent acquisitions funded partly through the revolver. Governance themes recur across the set: plurality director elections, advisory say-on-pay and say-on-frequency votes, and leadership transitions (NAPCO's CEO and Executive Chairman changes, IBEX's chairman transition and Lead Independent Director appointment, Bridgeway's fund complex migration to RBB). A notable procedural signal is CEA Industries/BNB Standard's failed equity plan vote under the former bylaw standard, which treated abstentions and broker non-votes as against, underscoring how voting mechanics can defeat shareholder-supported proposals. Executive compensation disclosure is thin in the excerpts provided, with NAPCO the only filing disclosing compensation-governance details, and no insider transaction or capital allocation data was present in the enriched fields for these filings.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 28, 2026

This IPO Pipeline digest covers a single US SEC filing dated 2026-10-28: a Form S-4 registration statement from Graf Global Corp., a Cayman Islands blank-check company (SPAC), tied to a proposed business combination with Halfcourt Holdco, Inc., a Delaware sports and recreational clubs/promotion company (SIC 7941) based in Miami Beach. The filing is preliminary and unpriced, subject to a Business Combination Agreement and closing conditions, and the excerpt contains no target financial results, so period-over-period comparisons, guidance, insider activity, and capital allocation data are not available to quantify. The materiality score is 6/10 with neutral sentiment, reflecting a de-SPAC pathway that is a meaningful pipeline event but lacks the financial detail needed for conviction. Portfolio-level patterns cannot be drawn from a single filing, so the key takeaway is process-oriented: the deal's progress will be determined by the S-4 amendment cycle, shareholder vote, and any disclosed target financials that follow.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — October 28, 2026

Both filings in this stream concern Nasdaq listing-compliance actions tied to sub-$1.00 share prices, which places them squarely within the Trading Suspension, Delisting, and Regulatory Halt scope. OSR Health (formerly OSR Holdings) is the more advanced case: Nasdaq trading has been suspended since August 26, 2026, the Hearings Panel has denied continued listing as of October 23, 2026, and the securities now trade OTC while the company evaluates options with an update promised by November 6, 2026. Milestone Pharmaceuticals is at an earlier stage, having received a Nasdaq deficiency letter on October 23, 2026 with a compliance deadline of April 21, 2027, and no present impact on its listing. The common thread is a bid-price problem that management has not solved through reverse splits in OSR's case, while Milestone retains the 180-day cure window and a possible transfer to the Nasdaq Capital Market. Both situations carry negative sentiment, with OSR rated more material (8/10) than Milestone (6/10). Enriched period-over-period financial metrics, insider activity, and capital allocation data were not supplied for either filing, so the quantitative read is limited to disclosed dates, deadlines, and terms rather than trend analysis. The practical implication is that trading-suspension and delisting risk is now concentrated in a single name already off Nasdaq, with a near-term catalyst date and a clear forced-decision point for the other.

2 high priority 2 total filings
· daily

US Executive Officer Management Changes SEC — October 28, 2026

Across the 35 filings in this Officer and Director Change stream, leadership turnover is the dominant theme, with CEO, CFO, COO and CAO transitions at GE HealthCare's PCS unit, Enanta, Parsons, Q2 Holdings, Align Technology, LENZ Therapeutics, Monroe Federal, Dropbox, ABM and Compass Minerals, alongside a steady flow of board appointments and departures. The strongest reported operating performance came from HF Sinclair (Q3 net income $2,015M vs $403M, adjusted refinery gross margin $54.22/bbl vs $19.16) and GE HealthCare (Adjusted EBIT margin up 180 bps to 16.6%, guidance raised), while Etsy showed accelerating GMS growth (+8.8% Y/Y) and Nextpower posted record revenue (+22.5% Y/Y). Credit and profitability stress is visible at Regional Management (net credit loss rate up 70 bps to 10.9%, 30+ day delinquencies up 50 bps to 7.5%) and LENZ Therapeutics (net loss widened to $31.0M from $16.7M, with a targeted 50%+ cut to 2027 operating expenses). Several filings explicitly state departures were not due to disagreements, which lowers governance-alarm readings for those names. Watch-worthy governance items include the CEO transitions at Align (Davis effective December 31, 2026) and Enanta, and the interim CFO roles at Parsons and Q2 Holdings.

35 high priority 35 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 28, 2026

Across the 35 filings, the dominant theme is leadership transition at the executive and board level, with CEO, CFO, COO, CAO and CTO changes concentrated in the 27 newly published filings. Several companies are restructuring leadership alongside operational shifts: LENZ Therapeutics is replacing its CEO as it cuts projected 2027 opex by more than 50%, Align Technology is installing a new CEO effective December 31, 2026, and Q2 Holdings and Parsons are using interim or dual-role CFO arrangements. Operating results are mixed rather than uniformly positive: HF Sinclair posted a sharp refining-driven earnings surge (Q3 net income of $2,015M vs $403M), Etsy and GE HealthCare showed accelerating top-line growth and margin expansion, while Nextpower saw gross margin fall 4.8 points sequentially despite record revenue, and Regional Management reported rising credit losses (+70 bps YoY to 10.9%). Board-composition changes skew toward independent and industry-experienced appointees (Gevo, ManpowerGroup, Arcutis, Vir, Churchill Downs), while several resignations (Garrett Motion, Bausch + Lomb, T-Mobile's Sievert, Red Robin) signal routine or negotiated exits rather than governance disputes, as each filing states no disagreement. Portfolio-level implication: leadership churn is elevated, so investors should weigh management continuity as a risk factor alongside reported financial momentum.

35 high priority 35 total filings